All In Biotech

Drug Trial Radar · NCT07923773

Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)

An Open-label Extension Study to Assess the Safety and Tolerability of DDY391 in Adult Participants With Active Moderate to Severe Psoriatic Arthritis Who Have Completed Study Treatment in CDDY391A12201

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Feb 10, 2027

Primary completion

Dec 12, 2029

Study completion Jan 11, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this 1-year open-label extension study is to characterize the longer-term safety and tolerability of DDY391 and to assess the durability of clinical response in participants with Psoriatic Arthritis (PsA) who have completed treatment in the CDDY391A12201 core study.

Conditions

  • Moderate to Severe Psoriatic Arthritis

Interventions

  • DDY391Drug

    DDY391

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 56 Weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.